August 3, 2020

TB Alliance Announces European Commission Authorisation of New Treatment for Highly Drug-Resistant Tuberculosis

Pretomanid, developed by the non-profit TB Alliance, has received EU marketing authorisation in combination regimen with bedaquiline and linezolid in adults with XDR-TB or treatment-intolerant/non-responsive MDR-TB
July 22, 2020

Global Health Leaders Chart the Path Forward in Pandemic Response

Dr. Anthony Fauci Calls for a Unified Approach and Continuous Commitment to Pandemic Preparedness
June 18, 2020

New Report Highlights Urgent Need for Improved Treatments for Children with MDR-TB

Tuberculosis is a leading cause of death worldwide. Children with drug-resistant TB need improved treatment options
June 5, 2020

Standing Against Racism and Injustice

A Message to the TB Alliance Family
June 2, 2020

InveniAI Announces Strategic Partnership with TB Alliance to Advance the Development of Transformative Therapies for Tuberculosis

TB Alliance to leverage AlphaMeld, an AI-powered platform to capture and accelerate innovation to address unmet needs
May 28, 2020

TB Alliance Commercialization Partner, Mylan, Launches Named Patient Access Program for New Highly Resistant TB Treatment

The NPAP is designed for patients in countries where regulatory approval or other access mechanisms are not yet available

Pages